Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
Inv. presentation
Acq. completed
Consulting agrmnt
Employment agrmnt
|
|
Theriva Biologics, Inc. (SYN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/03/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 08/16/2023 |
DEFR14A
| Form DEFR14A - Revised definitive proxy soliciting materials: |
| 08/15/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 08/14/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/11/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 08/02/2023 |
8-K
| Quarterly results |
| 06/08/2023 |
4
| SHALLCROSS STEVEN A (CEO and CFO) has filed a Form 4 on Theriva Biologics, Inc.|
Txns:
| Bought 14,000 shares
@ $0.6931, valued at
$9.7k
|
|
| 06/07/2023 |
4
| SHALLCROSS STEVEN A (CEO and CFO) has filed a Form 4 on Theriva Biologics, Inc.|
Txns:
| Bought 26,000 shares
@ $0.6328, valued at
$16.5k
|
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 03/30/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/30/2023 |
8-K
| Quarterly results |
| 03/10/2023 |
8-K
| Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Other Events, F... |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| SHALLCROSS STEVEN A (CEO and CFO) has filed a Form 4 on Theriva Biologics, Inc.|
Txns:
| Bought 25,000 shares
@ $0.9405, valued at
$23.5k
|
|
| 01/26/2023 |
4
| SHALLCROSS STEVEN A (CEO and CFO) has filed a Form 4 on Theriva Biologics, Inc.|
Txns:
| Bought 25,000 shares
@ $0.873, valued at
$21.8k
|
|
| 01/23/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/17/2023 |
8-K
| Quarterly results |
| 01/09/2023 |
8-K
| Quarterly results |
| 01/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/23/2022 |
8-K
| Quarterly results |
| 12/20/2022 |
8-K
| Quarterly results |
| 12/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/09/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 12/05/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 12/05/2022 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 10/17/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 10/12/2022 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial S... |
|
|
|